tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2024 Apr 26;30(6).
doi: 10.3201/eid3006.240051. Online ahead of print.
Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine
Xammy Huu Nguyenla, Timothy A Bates, Mila Trank-Greene, Mastura Wahedi, Fikadu G Tafesse, Marcel Curlin
Because novel SARS-CoV-2 variants continue to emerge, immunogenicity of XBB.1.5 monovalent vaccines against live clinical isolates needs to be evaluated. We report boosting of IgG (2.1×), IgA (1.5×), and total IgG/A/M (1.7×) targeting the spike receptor-binding domain and neutralizing titers against WA1 (2.2×), XBB.1.5 (7.4×), EG.5.1 (10.5×), and JN.1 (4.7×) variants.
Keywords: COVID-19; SARS; SARS-CoV-2; United States; allergy and immunology; antibodies; coronavirus; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccines; viruses.
. 2024 Apr 26;30(6).
doi: 10.3201/eid3006.240051. Online ahead of print.
Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine
Xammy Huu Nguyenla, Timothy A Bates, Mila Trank-Greene, Mastura Wahedi, Fikadu G Tafesse, Marcel Curlin
- PMID: 38669121
- DOI: 10.3201/eid3006.240051
Because novel SARS-CoV-2 variants continue to emerge, immunogenicity of XBB.1.5 monovalent vaccines against live clinical isolates needs to be evaluated. We report boosting of IgG (2.1×), IgA (1.5×), and total IgG/A/M (1.7×) targeting the spike receptor-binding domain and neutralizing titers against WA1 (2.2×), XBB.1.5 (7.4×), EG.5.1 (10.5×), and JN.1 (4.7×) variants.
Keywords: COVID-19; SARS; SARS-CoV-2; United States; allergy and immunology; antibodies; coronavirus; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccines; viruses.